中重度特应性皮炎患者经巴瑞替尼成功治疗后减量或停药与持续给药的疗效比较:来自长期扩展研究BREEZE-AD3的随机子研究
该随机子研究纳入526例在BREEZE-AD3第52周达到vIGA-AD 0/1/2的巴瑞替尼4mg或2mg治疗患者,再随机分为持续给药、减量或停药组。16周时,4mg队列持续给药、减量、停药组达到vIGA-AD 0/1的比例分别为51%、45%、30%;2mg队列分别为48%、42%、25%。减量后多数患者维持疗效,失去疗效者重新给药后多数可重获vIGA-AD 0/1/2。
要点
- 4mg队列16周时vIGA-AD 0/1比例:持续给药51%、减量45%、停药30%。
- 2mg队列16周时vIGA-AD 0/1比例:持续给药48%、减量42%、停药25%。
- 减量或停药后失去疗效者,重新给予原剂量后多数可重获vIGA-AD 0/1/2。
核心结论
- 巴瑞替尼允许患者灵活减量或停止治疗;减量治疗的患者中多数在16周内维持疗效。
- 多数因减量或停药而失去疗效的患者,在重新给予原剂量后获得临床相关疗效。
研究设计与样本
- 研究为正在进行的双盲III期长期扩展研究BREEZE-AD3(NCT03334435)的子研究,纳入526例患者。
- 患者进入BREEZE-AD3时接受巴瑞替尼4mg或2mg治疗,并在第52周达到vIGA-AD评分0(清除)、1(几乎清除)或2(轻度)。
- 接受巴瑞替尼4mg的患者被重新随机分配至巴瑞替尼4mg(持续给药)、巴瑞替尼2mg(减量)或安慰剂(停药,4mg队列)。
- 接受巴瑞替尼2mg的患者被重新随机分配至巴瑞替尼2mg(持续给药)、巴瑞替尼1mg(减量)或安慰剂(停药,2mg队列)。
- 16周后评估达到vIGA-AD 0/1、vIGA-AD 0/1/2、vIGA-AD≥3(失去疗效;重新给予原巴瑞替尼剂量的标准)的患者比例。
主要发现
- 4mg队列中,持续给药、减量和停药组达到vIGA-AD 0/1的患者比例分别为51%、45%和30%。
- 4mg队列中,持续给药、减量和停药组达到vIGA-AD 0/1/2的患者比例分别为87%、61%和50%。
- 2mg队列中,持续给药、减量和停药组达到vIGA-AD 0/1的患者比例分别为48%、42%和25%。
- 2mg队列中,持续给药、减量和停药组达到vIGA-AD 0/1/2的患者比例分别为92%、71%和45%。
- 4mg队列中,持续给药、减量和停药组vIGA-AD≥3的患者比例分别为39%、49%和56%;2mg队列分别为41%、41%和64%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib, an oral, selective Janus kinase 1/2 inhibitor, demonstrated long-term efficacy in moderate-to-severe atopic dermatitis in an ongoing double-blind, phase III, long-term extension study, BREEZE-AD3 (NCT03334435). OBJECTIVES: To evaluate the efficacy and safety of downtitration and treatment withdrawal in a substudy of BREEZE-AD3. METHODS: The substudy included patients (N = 526) treated with baricitinib 4 mg or 2 mg at entry into BREEZE-AD3 who achieved a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) scale score of 0 (clear), 1 (almost clear) or 2 (mild) at week 52. Patients treated with baricitinib 4 mg were rerandomized to baricitinib 4 mg (continuous dosing), baricitinib 2 mg (downtitration) or placebo (treatment withdrawal, 4-mg cohort), and patients treated with baricitinib 2 mg were rerandomized to baricitinib 2 mg (continuous dosing), baricitinib 1 mg (downtitration), or placebo (treatment withdrawal, 2-mg cohort). After 16 weeks, we assessed the proportion of patients with vIGA-AD® 0/1, vIGA-AD® 0/1/2, vIGA-AD® ≥ 3 (loss of response; criterion to readminister the original baricitinib dose) and for patients who were readministered the original baricitinib dose, we assessed the proportion of patients who recaptured vIGA-AD® 0/1/2 within 16 weeks of treatment readministration (patients in the continuous dosing maintained the same dose). RESULTS: For the continuous dosing, downtitration, and treatment withdrawal groups 51%, 45% and 30% of patients in the 4-mg cohort achieved vIGA-AD® 0/1 and 87%, 61% and 50% of patients achieved vIGA-AD® 0/1/2, respectively. For the 2-mg cohort, the respective proportions of patients were 48%, 42% and 25% for vIGA-AD® 0/1 and 92%, 71% and 45% for vIGA-AD® 0/1/2. The respective proportions of patients with vIGA-AD® ≥ 3 were 39%, 49% and 56% in the 4-mg cohort and 41%, 41% and 64% in the 2-mg cohort. Of those who were readministered the original baricitinib dose, the proportions of patients who recaptured vIGA-AD® 0/1/2 among the continuous dosing, downtitration, and treatment withdrawal groups were 80%, 85% and 88% in the 4-mg cohort and 90%, 56% and 86% in the 2-mg cohort, respectively. CONCLUSIONS: Baricitinib allows flexibility for patients to downtitrate or stop treatment. For patients who downtitrated treatment, the majority maintained efficacy through 16 weeks. Most patients who lost efficacy with downtitration or treatment withdrawal achieved clinically relevant efficacy upon readministration of their original dose.
引用
- Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023. PMID: 36763879. doi:10.1093/bjd/ljac057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。